Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Harmony Biosciences Holdings Q3 2026 Results: Net Income $48.2M, Down 5.2% YoY

Harmony Biosciences reported net product revenue of $268.9 million for the third quarter of 2026, a 12.3% increase year-over-year. Net income for the nine months ended September 30, 2026, rose to $156.1 million compared to $136.2 million in the prior year, despite higher operating expenses driven by research and development.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue268.9239.5
Gross profit188.2179.8
Profit before tax59.267.5
Net income48.250.9
EPS (diluted, $ a share)$0.81$0.87

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Net income, year on year-5.2%
Revenue, year on year+12.3%
Gross margin70.0%
Operating margin20.2%
Source

10-Q filed with the SEC, NASDAQ: HRMY. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Harmony Biosciences Holdings, Inc.: key numbers

Share price
$32.96Close, Nov 16
Market cap
$1.94B
Shares outstanding
58.72MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Harmony Biosciences Holdings, Inc.

All →
8:01 AM ET 8-K
Financial Results

Harmony Biosciences Holdings Financial Results

Harmony Biosciences reported Q3 2026 financial results with WAKIX net revenue of $269 million, driven by 400 net patient additions. The company reaffirmed its full-year 2026 revenue guidance of $1.0 billion to $1.04 billion and announced that Peter Anastasiou will succeed Jeffrey Dayno as CEO effective January 1, 2027.

“As I prepare to transition the President and CEO role to Peter on January 1, I believe Harmony is operating from a position of strength, with a durable and growing WAKIX franchise, the financial flexibility to invest in innovation, conviction to pursue strategic business development opportunities, and a pipeline led by BP-205 that has the potential to generate significant long-term value.”

Jeffrey Dayno, MD, President and Chief Executive Officer

“I am proud of the talented team and passionate organization we have built, which position Harmony for continued success in delivering innovative treatments to patients and sustained value for our shareholders.”

Jeffrey Dayno, MD, President and Chief Executive Officer
4:15 PM ET 8-K/A
Executive Compensation

Harmony Biosciences Holdings Executive Compensation

Harmony Biosciences announced the compensation terms for its leadership succession plan, including a separation and consulting agreement for retiring CEO Jeffrey M. Dayno and an amended employment agreement for incoming CEO Peter Anastasiou. Dr. Dayno will serve as a non-executive advisor through January 2028 at a rate of $500 per hour with continued equity vesting, while Mr. Anastasiou's new terms as President and CEO take effect January 1, 2027.

Term
through Jan 2028
8:00 AM ET 8-K
Leadership Change

Harmony Biosciences Holdings Leadership Change

Harmony Biosciences announced that Jeffrey M. Dayno, M.D., will retire as President, CEO, and Director effective December 31, 2026. Peter Anastasiou, the company's current Chief Operating Officer and former board member, has been appointed to succeed him as President, CEO, and Director effective January 1, 2027. Dr. Dayno will remain with the company as a non-executive advisor through 2027 to support the transition.

4:48 PM ET Form 4
Insider Selling

Harmony Biosciences Holdings CMO Kumar Budur Sells $1.66M of Stock

Kumar Budur, CMO, sold 38,452 shares of Harmony Biosciences Holdings, Inc. at $43.00 to $43.05 a share (average $43.05) in 3 transactions, worth $1.66M in total between Sep 16, 2026 and Sep 18, 2026. Shares held after the trade: 13,115 (-73.2%).

Value
$1.66M
Shares
38,452
Average price
$43.05
Role
CMO
Holding change
-73.2%
Trade date
Sep 16, 2026 to Sep 18, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.